#ESMO26: The benefits of systemic treatment intensification in very high-risk, localised and relapsed #ProstateCancer treated with radiotherapy were shown in the phase II DASL-HiCaP #ClinicalTrial. A superior 4-year metastasis-free survival rate was seen with the addition of the androgen receptor pathway inhibitor (#ARPI), darolutamide, to radiotherapy and androgen deprivation therapy (#ADP), compared with standard of care, supporting earlier evidence from the STAMPEDE trial.
A substudy of the PROTEUS phase II trial found that peri-operative use of the ARPI, apalutamide, alongside ADP, in patients with localised high-risk prostate cancer undergoing radical prostatectomy was associated with superior event-free survival, metastasis-free survival and time to subsequent treatment than radical prostatectomy plus pelvic lymph node dissection.
Read the latest news: https://ow.ly/jIi850ZZYxe
#InsightsbyESMO #CancerResearch #MedicalOncology
118 浏览 · 0 赞 · 0 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com